NEW YORK — Theravance and GlaxoSmithKline said Friday that their lung disease drug Breo Ellipta worked as a treatment for asthma in a clinical trial.
The companies said patients who took Breo Ellipta had a bigger improvement in lung function than patients who took the drug Flonase, which contains one of Breo Ellipta’s two main components. Breo Ellipta is approved as a treatment for chronic obstructive pulmonary disease.
The most common side effects of treatment included headache, upper respiratory tract infection, and flu.
The companies launched the drug in the U.S. on Oct. 30. The drug is also approved in Canada and Japan. It is sold in Japan as Relvar Ellipta.
Shares of California-based Theravance Inc. picked up 98 cents, or 2.8 percent, to $36.53 in late morning trading. GlaxoSmithKline PLC’s U.S. shares rose 30 cents to $52.52.